|(A;G)||2||1,51x increased Coronary Heart disease risk|
|(G;G)||3||2,57x increased Coronary Heart disease risk|
[PMID 20160194] Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians
[PMID 20605575] Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus
[PMID 21900290] Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes
[PMID 22368281] Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a).
|Title||Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.|
|Odds Ratio||6.8000 None|
[PMID 21127300] Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk.
[PMID 21252144] Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
[PMID 21283670] Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans.
[PMID 21305047] Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey.
[PMID 22560621] Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
|Trait||Lipoprotein-associated phospholipase A2 activity change in response to statin therapy|
|Title||Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.|
|Odds Ratio||4.80 [0.82-2.78] percent increase|
[PMID 23735648] Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease
[PMID 23978127] Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention
[PMID 24161338] Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
|Title||Genetic associations with valvular calcification and aortic stenosis.|
|Odds Ratio||2.05 [1.66-2.53]|
[PMID 24622370] Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
[PMID 22898070] Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.
[PMID 23100282] Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
[PMID 23278389] Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene.
[PMID 23375930] Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.
[PMID 24776095] LPA rs10455872 polymorphism is associated with coronary lesions in Brazilian patients submitted to coronary angiography
[PMID 24903972] Genetic predisposition to calcific aortic stenosis and mitral annular calcification
|Trait||Coronary artery disease or ischemic stroke|
|Title||Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.|
|Odds Ratio||NR NR|
[PMID 24760552] Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts
[PMID 26564469] Advances in the Association between Apolipoprotein(a)Gene Polymorphisms and Coronary Heart Disease
|Disease||HMG CoA reductase inhibitors response - Efficacy|
|CLNDBN||HMG CoA reductase inhibitors response - Efficacy|
|CLNSRC||PharmGKB Clinical Annotation|
[PMID 27831500] The LPA Gene, Ethnicity, and Cardiovascular Events.
[PMID 28566218] Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
[PMID 29703846] LPA Variants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins.
[PMID 30594920] Investigation of LPA sequence variants rs6415084, rs3798220 with conventional coronary artery disease in Iranian CAD patients.
[PMID 30759150] Using topic modeling via non-negative matrix factorization to identify relationships between genetic variants and disease phenotypes: A case study of Lipoprotein(a) (LPA).
[PMID 32152647] Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.
[PMID 32220223] Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification.
[PMID 32343731] A genome-wide analysis of DNA methylation identifies a novel association signal for Lp(a) concentrations in the LPA promoter.